…
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public filings and company disclosures for Greater Cannabis Company Inc (PINK: GCAN) are limited, offering little verifiable operational or financial detail. Listed as a cannabis-sector issuer, it may benefit from long-term growth in legalized markets and potential industry consolidation if management develops operations and improves transparency.
Key risks include minimal public disclosure, OTC Pink listing with low liquidity, regulatory uncertainty for cannabis businesses, and execution and financing risk common to small, underreported issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -0.33M | -0.18M | -0.19M | -0.36M | -0.60M |
| Net income | -0.33M | -0.18M | -0.19M | -0.54M | -0.51M |
| Selling general administrative | 0.12M | 0.12M | 0.12M | 0.12M | 0.15M |
| Gross profit | -0.00M | 0.00M | -0.01M | -0.05M | -0.00M |
| Reconciled depreciation | 0.00M | 0.01M | 0.01M | 0.01M | 0.01M |
| Ebit | -0.33M | -0.16M | -0.18M | -0.18M | -0.34M |
| Ebitda | -0.33M | -0.15M | -0.17M | -0.23M | -0.72M |
| Depreciation and amortization | 0.00M | 0.01M | 0.01M | -0.06M | -0.37M |
| Operating income | -0.18M | -0.16M | -0.18M | -0.18M | -0.34M |
| Other operating expenses | 0.18M | - | 0.18M | 0.18M | 0.36M |
| Interest expense | 0.00M | 0.02M | 0.01M | 0.12M | 0.29M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.00M | -0.02M | -0.02M | -0.12M | -0.29M |
| Income tax expense | - | - | - | 0.18M | -0.09M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Total operating expenses | 0.18M | 0.16M | 0.17M | 0.18M | 0.34M |
| Cost of revenue | 0.00M | 0.00M | 0.01M | 0.05M | 0.01M |
| Total other income expense net | -0.15M | -0.02M | -0.01M | -0.18M | -0.26M |
| Net income from continuing ops | -0.33M | -0.18M | -0.19M | -0.36M | -0.60M |
| Net income applicable to common shares | - | - | - | - | -0.60M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.00M | 0.06M | 0.17M | 0.28M | 0.39M |
| Intangible assets | - | 0.00M | 0.01M | 0.01M | 0.02M |
| Total liab | 0.74M | 0.90M | 0.83M | 0.83M | 0.86M |
| Total stockholder equity | -0.74M | -0.84M | -0.66M | -0.54M | -0.47M |
| Other current liab | 0.47M | 0.46M | 0.40M | 0.31M | 0.22M |
| Common stock | 1.35M | 0.80M | 0.80M | 0.73M | 0.51M |
| Capital stock | 1.36M | 0.81M | 0.81M | 0.74M | 0.52M |
| Retained earnings | -4.99M | -4.66M | -4.48M | -4.29M | -3.93M |
| Cash | 0.00M | 0.06M | 0.17M | 0.27M | 0.38M |
| Total current liabilities | 0.74M | 0.90M | 0.83M | 0.83M | 0.86M |
| Net debt | 0.26M | 0.37M | 0.26M | 0.23M | 0.25M |
| Short term debt | 0.26M | 0.43M | 0.43M | 0.50M | 0.63M |
| Short long term debt | 0.26M | 0.43M | 0.43M | 0.50M | 0.63M |
| Short long term debt total | 0.26M | 0.43M | 0.43M | 0.50M | 0.63M |
| Other stockholder equity | 2.89M | 3.01M | 3.81M | 3.01M | 2.95M |
| Total current assets | 0.00M | 0.06M | 0.17M | 0.27M | 0.38M |
| Net tangible assets | - | - | - | - | -0.49M |
| Accounts payable | 0.01M | 0.01M | 0.01M | 0.02M | 0.01M |
| Accumulated other comprehensive income | - | - | -0.80M | - | - |
| Non currrent assets other | - | 0.00M | 0.00M | - | - |
| Non current assets total | 0.00M | 0.00M | 0.01M | 0.01M | 0.02M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to liabilities | - | - | - | - | 0.00M |
| Net borrowings | 0.00M | 0.00M | 0.00M | - | 0.50M |
| Total cash from financing activities | 0.00M | 0.00M | 0.00M | 0.00M | 0.50M |
| Change to operating activities | - | - | - | - | 0.12M |
| Net income | -0.33M | -0.18M | -0.19M | -0.36M | -0.60M |
| Change in cash | -0.06M | -0.11M | -0.10M | -0.11M | 0.26M |
| Begin period cash flow | 0.06M | 0.17M | 0.27M | 0.38M | 0.11M |
| End period cash flow | 0.00M | 0.06M | 0.17M | 0.27M | 0.38M |
| Total cash from operating activities | -0.06M | -0.11M | -0.10M | -0.11M | -0.24M |
| Depreciation | 0.00M | 0.01M | 0.01M | 0.01M | 0.01M |
| Other cashflows from financing activities | 0.00M | - | - | - | 0.50M |
| Change to netincome | - | - | - | - | -0.03M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.09M | 0.06M | 0.08M | 0.09M | 0.12M |
| Stock based compensation | 0.00M | 0.04M | 0.08M | - | - |
| Other non cash items | 0.18M | 0.06M | -0.08M | 0.16M | 0.24M |
| Free cash flow | -0.06M | -0.11M | -0.10M | -0.11M | -0.24M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GCAN Greater Cannabis Company Inc |
-0.06 7.35% |
0.75 | - | - | 39.37 | - | 71.46 | -2.33 |
| MKKGY Merck KGaA ADR |
0.40 1.22% |
33.13 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
169.65 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
- -% |
21.64 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.15 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.
| Name | Title | Year Born |
|---|---|---|
| Mr. Aitan Zacharin | Chairman, Pres, CEO, Acting CFO & Treasurer | 1983 |
| Mr. Aitan Zacharin | Chairman, President, CEO, Acting CFO & Treasurer | 1983 |
| Motti Stenge | Chief Operating Officer | NA |
| Dr. Adi Aran M.D. | Chief Scientific Advisor | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.